drugset / Trial / NCT00973271

Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

NCT00973271

Phase 3 Withdrawn Essentialis, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The hypothesis of this study is that DCCR is effective as both monotherapy and in combination with a statin in lowering triglycerides in subjects with very high triglycerides

Timeline

Start
2011-03
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazoxide Choline Unknown 290 mg
Subject Diazoxide Choline Unknown 435 mg
Comparator fenofibric acid Small molecule 135 mg
Background Atorvastatin Small molecule 20 mg

Indications